BioCardia, Inc. (BCDA)
After hours:
| Previous close | 0.4060 |
| Open | 0.3800 |
| Bid | 0.2608 x 200 |
| Ask | 0.3940 x 200 |
| Day's range | 0.3007 - 0.3800 |
| 52-week range | 0.3000 - 2.9200 |
| Volume | |
| Avg. volume | 330,600 |
| Market cap | 11.085M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBioCardia Announces Reverse Stock Split
SUNNYVALE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the Company's stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. The reverse stock split will become effective at 12:01 a.m. Eastern
- GuruFocus.com
BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...
Discover how BioCardia Inc navigates clinical advancements and financial efficiencies in the first quarter of 2024.
- GlobeNewswire
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2024 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2024 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlight
